Analyst Price Targets — EYPT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 2, 2026 6:04 am | — | China Renaissance Securities (US) Inc. | $4.00 | $4.58 | StreetInsider | TD Cowen Downgrades EyePoint Inc. (EYPT) to Hold |
| August 18, 2026 12:01 pm | — | Chardan Capital | $5.00 | $5.31 | TheFly | EyePoint downgraded to Neutral from Buy at Chardan |
| August 18, 2026 12:51 am | — | RBC Capital | $5.00 | $4.87 | TheFly | EyePoint downgraded to Sector Perform from Outperform at RBC Capital |
| August 17, 2026 4:35 pm | — | Jefferies | $8.00 | $4.61 | TheFly | EyePoint price target lowered to $8 from $30 at Jefferies |
| August 6, 2026 10:17 am | — | H.C. Wainwright | $27.00 | $12.25 | TheFly | EyePoint price target lowered to $27 from $30 at H.C. Wainwright |
| July 29, 2026 10:53 am | Graig Suvannavejh | Mizuho Securities | $39.00 | $11.96 | StreetInsider | EyePoint Inc. (EYPT) PT Raised to $39 at Mizuho, 'Top Pick' |
| July 15, 2026 8:12 pm | Annabel Samimy | Stifel Nicolaus | $40.00 | $13.85 | TheFly | EyePoint initiated with a Buy at Stifel |
| February 19, 2026 12:17 pm | — | Mizuho Securities | $36.00 | $14.36 | TheFly | EyePoint price target raised to $36 from $33 at Mizuho |
| February 5, 2026 1:54 pm | Lisa Walter | RBC Capital | $39.00 | $13.22 | StreetInsider | RBC Capital on EyePoint Inc. (EYPT): 'We See Recent Weakness as Buying Opportunity' |
| October 29, 2025 12:50 pm | Graig Suvannavejh | Mizuho Securities | $33.00 | $12.25 | TheFly | EyePoint price target raised to $33 from $28 at Mizuho |
Latest News for EYPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT PR Newswire
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In EyePoint (EYPT) To Contact Him Directly To Discuss Their Options
Markets took a beating Tuesday as war tensions, surging oil, and the September curse hammered stocks, bonds, and gold all at once. Find out which stocks Wall Street upgraded, downgraded, or initiated fresh coverage on as analysts scramble to reposition heading into a brutal stretch.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EYPT.
U.S. House Trading
No House trades found for EYPT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.